<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05109793</url>
  </required_header>
  <id_info>
    <org_study_id>AZA-001-5A4-01</org_study_id>
    <nct_id>NCT05109793</nct_id>
  </id_info>
  <brief_title>GM1 and GM2 Gangliosidosis PROspective Neurological Disease TrajectOry Study (PRONTO)</brief_title>
  <acronym>PRONTO</acronym>
  <official_title>Prospective Longitudinal Study of Neurological Disease Trajectory in Children Living With Late-Infantile or Juvenile Onset of GM1 or GM2 Gangliosidosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Azafaros A.G.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Azafaros A.G.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study aims to characterize prospectively longitudinal progression of neurological domains&#xD;
      in GM1 and GM2 Gangliosidosis patients with high-quality standard (GCP compliant).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is a prospective longitudinal, multicentric decentralized trial which will be&#xD;
      performed in children diagnosed with late infantile or juvenile onset of neurological disease&#xD;
      of either GM1 or GM2 Gangliosidoses (Tay-Sachs or Sandhoff disease). The study plans to&#xD;
      enroll at least 75 patients worldwide. A large set of neurological functions will be&#xD;
      evaluated by rating scales used by physicians and questionnaires answered by parents. Digital&#xD;
      tools will be used to support the study procedures with virtual visits and also a passive&#xD;
      monitoring approach with a medical device.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 1, 2021</start_date>
  <completion_date type="Anticipated">November 1, 2025</completion_date>
  <primary_completion_date type="Anticipated">November 1, 2025</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change in the Gait 9-point item score of the Scale for Assessment and Rating of Ataxia (SARA)</measure>
    <time_frame>0-4 years</time_frame>
    <description>Score between 0 (better) and 8 (worse) points</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in the Speech 7-point item score of SARA</measure>
    <time_frame>0-4 years</time_frame>
    <description>Score between 0 (better) and 6 (worse) points</description>
  </primary_outcome>
  <other_outcome>
    <measure>Change in scores of SARA items Stance (7-point), Sitting (5-point), Finger chase (5-point), Nose-finger test (5-point), Fast alternating hand movement (5-point), Heel-shin slide (5-point) and overall score.</measure>
    <time_frame>0-4 years</time_frame>
    <description>Stance score between 0 (better) and 6 (worse) points Sitting score between 0 (better) and 4 (worse) points Finger chase test score between 0 (better) and 4 (worse) points Nose-finger test score between 0 (better) and 4 (worse) points Fast alternating hand movements test score between 0 (better) and 4 (worse) points Heel-shin slide score between 0 (better) and 4 (worse) points</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in the total score of the Motor Function Measure-32 (MFM-32), and each of the 3 domains</measure>
    <time_frame>0-4 years</time_frame>
    <description>The scoring of each item uses a 4-point Likert scale - score between 0 (worse) and 3 (better)</description>
  </other_outcome>
  <other_outcome>
    <measure>Change of Timed Up &amp; Go</measure>
    <time_frame>0-4 years</time_frame>
    <description>Time a patient takes to rise from a chair, walk 3 meters, turn around 180°, walk back to the chair, and sit down while turning 180°</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in swallowing score</measure>
    <time_frame>0-4 years</time_frame>
    <description>Assessment of patient swallowing ability - score between 0 (better) and 5 (worse)</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in the overall composite score of the Vineland Adaptive Behavioral Scale (VABS)</measure>
    <time_frame>0-4 years</time_frame>
    <description>Rated on 0 (never performed),1, 2 (habitually performed) scale</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in BSFC-s score for each of the 10 items and overall score</measure>
    <time_frame>0-4 years</time_frame>
    <description>Rated on a 4-point scale with the values &quot;strongly disagree&quot;, &quot;disagree&quot;, &quot;agree&quot;, and &quot;strongly agree&quot;</description>
  </other_outcome>
  <other_outcome>
    <measure>Collection of seizures events, choking episodes, respiratory tract infections</measure>
    <time_frame>0-4 years</time_frame>
    <description>Gathering data about presence/absence and frequency of seizures, choking episodes, respiratory tract infections</description>
  </other_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">75</enrollment>
  <condition>GM1 Gangliosidosis</condition>
  <condition>Sandhoff Disease</condition>
  <condition>Tay-Sachs Disease</condition>
  <arm_group>
    <arm_group_label>Cohort</arm_group_label>
    <description>Late infantile or juvenile onset for GM1 or GM2 Gangliosidosis. This study will enrol a minimum of 75 patients in total, including at least 25 patients with GM1 Gangliosidosis and 25 patients with GM2 Gangliosidosis</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Individuals with diagnosis of GM1 Gangliosidosis Tay-Sachs disease, or Sandhoff disease, or&#xD;
        late infantile or juvenile onset of neurological disease&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Genetically confirmed GM1 Gangliosidosis or genetically confirmed Tay-Sachs or&#xD;
             Sandhoff disease&#xD;
&#xD;
          -  Onset of neurological symptoms on or after the patient's first birthday&#xD;
&#xD;
          -  Achieved 12-month developmental milestones at normal developmental time points as per&#xD;
             Principal Investigator's judgement&#xD;
&#xD;
          -  Abnormal gait and/or speech disturbance&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who have received (within 6 months before screening), are currently receiving&#xD;
             or are planned to receive (within the following 6 months) gene therapy, stem cell&#xD;
             transplantation, experimental drugs, or any drug, which, in the Investigator´s&#xD;
             opinion, may (have) interfere(d) with disease progression&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>20 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ruben Giorgino, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Azafaros A.G.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Cécile Paquet-Luzy</last_name>
    <phone>+ 41 79 631 71 46</phone>
    <email>cecile.paquet-luzy@azafaros.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Emilie Doppler</last_name>
    <email>emilie.doppler@azafaros.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hopital d'Enfants CHU Timone</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Armand-Trousseau Children's Hospital - CHU Paris Est</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 8, 2021</study_first_submitted>
  <study_first_submitted_qc>October 25, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 5, 2021</study_first_posted>
  <last_update_submitted>October 25, 2021</last_update_submitted>
  <last_update_submitted_qc>October 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>GM1 Gangliosidosis</keyword>
  <keyword>GM2 Gangliosidosis</keyword>
  <keyword>Natural History Study</keyword>
  <keyword>Lysosomal Storage Disorders</keyword>
  <keyword>Nervous System Diseases</keyword>
  <keyword>Tay-Sachs disease</keyword>
  <keyword>Sandhoff disease</keyword>
  <keyword>Genetic Diseases, Inborn</keyword>
  <keyword>Hexosaminidase A and B deficiency</keyword>
  <keyword>β-galactosidase deficiency</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nervous System Diseases</mesh_term>
    <mesh_term>Gangliosidoses</mesh_term>
    <mesh_term>Tay-Sachs Disease</mesh_term>
    <mesh_term>Gangliosidosis, GM1</mesh_term>
    <mesh_term>Sandhoff Disease</mesh_term>
    <mesh_term>Gangliosidoses, GM2</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

